Saxagliptin: A DPP-4 Inhibitor for Type 2 Diabetes Management

What is Saxagliptin?

Saxagliptin is an oral antidiabetic medication that belongs to a class of drugs called dipeptidyl peptidase-4 (DPP-4) inhibitors. It is primarily prescribed to help control blood sugar levels in adults with type 2 diabetes mellitus. This medication works by enhancing the body’s natural ability to regulate glucose levels, particularly after meals.

Uses

Saxagliptin has several documented medical uses:

• Type 2 diabetes management: Used as monotherapy or in combination with other antidiabetic medications to improve glycemic control in adults
• Combination therapy with metformin: Often prescribed alongside metformin for enhanced blood sugar control when metformin alone is insufficient
• Combination with insulin: May be used with insulin therapy to help reduce insulin requirements and improve overall glucose management
• Combination with sulfonylureas: Can be paired with sulfonylurea medications for patients requiring multiple antidiabetic agents
• Post-meal glucose control: Particularly effective at reducing blood sugar spikes that occur after eating

How it works

Saxagliptin works by blocking the enzyme dipeptidyl peptidase-4 (DPP-4), which normally breaks down incretin hormones like GLP-1 and GIP. By inhibiting this enzyme, saxagliptin allows these beneficial hormones to remain active longer, leading to increased insulin release when blood sugar is elevated and decreased glucagon production when it’s not needed. This glucose-dependent mechanism helps lower blood sugar levels without causing hypoglycemia when glucose levels are normal.

Side effects

Common side effects:

Submit Your Paper

• Upper respiratory tract infections
• Urinary tract infections
• Headache
• Nausea
• Abdominal pain
• Diarrhea
• Dizziness
• Fatigue

Serious side effects to watch for:

• Severe allergic reactions (swelling of face, lips, throat, difficulty breathing)
• Acute pancreatitis (severe abdominal pain that may radiate to the back)
• Heart failure symptoms (shortness of breath, swelling in legs or feet)
• Severe joint pain
• Skin reactions including blistering or peeling

Warnings and precautions

• Kidney function: Dosage adjustments are required for patients with moderate to severe kidney impairment, and the medication should be used cautiously in those with end-stage renal disease
• Heart failure risk: Patients with a history of heart failure should be monitored closely, as DPP-4 inhibitors may increase the risk of heart failure hospitalization
• Pregnancy and breastfeeding: Safety during pregnancy has not been established; the medication should only be used if the potential benefit justifies the potential risk to the fetus
• Pancreatitis history: Patients with a history of pancreatitis should be monitored carefully, as there may be an increased risk of acute pancreatitis
• Immune system effects: The medication may affect immune function, potentially increasing susceptibility to infections

Interactions

• Strong CYP3A4 inhibitors (ketoconazole, ritonavir): May increase saxagliptin levels, requiring dose reduction to 2.5 mg daily
• Insulin and insulin secretagogues: May increase the risk of hypoglycemia when used together, requiring careful blood sugar monitoring
• Digoxin: Saxagliptin may slightly increase digoxin levels, requiring monitoring of digoxin concentrations
• Warfarin: May affect anticoagulation; INR monitoring may be needed when starting or stopping saxagliptin
• Corticosteroids: May counteract the blood sugar-lowering effects of saxagliptin
• Diuretics: May affect kidney function and saxagliptin elimination
• ACE inhibitors: Combination may increase the risk of angioedema in susceptible patients
• St. John’s Wort: May decrease saxagliptin effectiveness by increasing its metabolism

Check interactions with the GMJ Interaction Checker

Dosage

The typical adult dosage of saxagliptin is 2.5 mg or 5 mg taken once daily, with or without food. For patients with moderate to severe kidney impairment or those taking strong CYP3A4 inhibitors, the recommended dose is 2.5 mg once daily. Patients with end-stage renal disease requiring hemodialysis should take the medication after dialysis. Dosage should always be individualized and determined by a healthcare provider based on the patient’s kidney function, other medications, and overall health status.

Sources: FDA DailyMed drug labels (public domain), BNF, WHO Essential Medicines List. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting or stopping any medication.

This work is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). You are free to share and adapt this content with attribution to GMJ News (news.gmj.ge).